BIOV — Biovaxys Technology Income Statement
0.000.00%
Last trade - 00:00- CA$16.87m
- CA$16.86m
Annual income statement for Biovaxys Technology, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2018 October 31st | R2019 October 31st | 2020 October 31st | 2021 October 31st | 2022 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.161 | 0.217 | 1.1 | 6.44 | 11.7 |
| Operating Profit | -0.161 | -0.217 | -1.1 | -6.44 | -11.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.161 | -0.217 | -1.1 | -6.46 | -11.7 |
| Net Income After Taxes | -0.161 | -0.217 | -1.1 | -6.46 | -11.7 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -0.161 | -0.23 | -1.17 | -6.46 | -11.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.161 | -0.23 | -1.17 | -6.46 | -11.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.008 | -0.01 | -0.039 | -0.078 | -0.042 |
| Dividends per Share |